Michael Yu, Innovent CEO

In­novent show­cas­es topline PhII win for high-dose obe­si­ty drug in Chi­na

In­novent is of­fer­ing up a fresh look at its obe­si­ty drug can­di­date, show­cas­ing an av­er­age 15.4% place­bo-ad­just­ed weight loss af­ter 24 weeks of treat­ment in a Phase II Chi­na study as it looks to make a mark in the large Asian mar­ket.

The new da­ta come a year af­ter In­novent last tout­ed mid-stage re­sults around maz­du­tide, a dual ag­o­nist of glucagon-like pep­tide-1 re­cep­tor (GLP-1R) and glucagon re­cep­tor (GC­GR) orig­i­nal­ly from Eli Lil­ly. While the pre­vi­ous tri­al test­ed mul­ti­ple dose ranges up to 6 mg and en­rolled peo­ple who were both over­weight and obese, the new tri­al ze­roed in on obese pa­tients with a body mass in­dex at or above 30.0 kg/m2. Pa­tients were al­so giv­en a high­er 9 mg dose.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.